The Important Role of Cuproptosis and Cuproptosis-related Genes in the Development of Thyroid Carcinoma Revealed by Transcriptomic Analysis and Experiments

Overview

Journal Braz J Otorhinolaryngol

Date 2025 Feb 6

PMID 39914044

Authors

Yani Liu

Yanyan He

Shizhen Lei

Affiliations

Soon will be listed here.

Abstract

Objective: Programmed Cell Death (PCD) processes have been suggested to play a role in the development of cancers. The study aimed to investigate the enrichment of different types of PCD and identify important PCD-related genes in Thyroid Carcinoma (THCA).

Methods: The whole study is based on transcriptomic analysis and Immunohistochemistry (IHC) experiments. For transcriptomic analysis, the transcriptomic data of THCA (n = 493) and normal thyroid samples (n = 58) was used. The enrichment score of different types of PCD in THCA samples was calculated and the most enriched PCD process was identified. Then the expression of PCD-related genes in control and THCA samples were compared and the association between cuproptosis and characteristics of Tumor Microenvironment (TME) in THCA tissues was explored. IHC experiment was performed to confirm gene expressions in THCA and para-tumor samples.

Results: Enrichment analysis showed that cuproptosis was the most enriched type of PCD process and associated with malignancy in THCA. The expression of a cuproptosis-related gene, CDKN2A, was found and confirmed to be higher in THCA than normal samples and associated with poor outcomes and higher clinical stages of patients with THCA. Moreover, CDKN2A expression was associated with immunosuppressive TME in THCA.

Conclusion: Our findings indicated the important role of cuproptosis and a cuproptosis-related gene, CDKN2A, in the development and progression of THCA, which might provide novel insights into the understanding of pathophysiology of THCA.

References

Fan K, Dong Y, Li T, Li Y . Cuproptosis-associated CDKN2A is targeted by plicamycin to regulate the microenvironment in patients with head and neck squamous cell carcinoma. Front Genet. 2023; 13:1036408. PMC: 9868476. DOI: 10.3389/fgene.2022.1036408. View

Wlodkowic D, Telford W, Skommer J, Darzynkiewicz Z . Apoptosis and beyond: cytometry in studies of programmed cell death. Methods Cell Biol. 2011; 103:55-98. PMC: 3263828. DOI: 10.1016/B978-0-12-385493-3.00004-8. View

Cesano A, Warren S . Bringing the next Generation of Immuno-Oncology Biomarkers to the Clinic. Biomedicines. 2018; 6(1). PMC: 5874671. DOI: 10.3390/biomedicines6010014. View

Li X, Jing Z, Li X, Liu L, Xiao X, Zhong Y . The role of exosomes in cancer-related programmed cell death. Immunol Rev. 2023; 321(1):169-180. DOI: 10.1111/imr.13286. View

Babak M, Ahn D . Modulation of Intracellular Copper Levels as the Mechanism of Action of Anticancer Copper Complexes: Clinical Relevance. Biomedicines. 2021; 9(8). PMC: 8389626. DOI: 10.3390/biomedicines9080852. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Adib E, Nassar A, Akl E, Abou Alaiwi S, Nuzzo P, Mouhieddine T . Alterations and Response to Immunotherapy in Solid Tumors. Clin Cancer Res. 2021; 27(14):4025-4035. PMC: 8900067. DOI: 10.1158/1078-0432.CCR-21-0575. View

Galluzzi L, Vitale I, Aaronson S, Abrams J, Adam D, Agostinis P . Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018; 25(3):486-541. PMC: 5864239. DOI: 10.1038/s41418-017-0012-4. View

Davis C, Gu X, Kiefer R, Ralle M, Gade T, Brady D . Altered copper homeostasis underlies sensitivity of hepatocellular carcinoma to copper chelation. Metallomics. 2020; 12(12):1995-2008. PMC: 8315290. DOI: 10.1039/d0mt00156b. View

10.

Stockwell B . Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022; 185(14):2401-2421. PMC: 9273022. DOI: 10.1016/j.cell.2022.06.003. View

11.

Gutiontov S, Turchan W, Spurr L, Rouhani S, Chervin C, Steinhardt G . CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021; 11(1):20059. PMC: 8501138. DOI: 10.1038/s41598-021-99524-1. View

12.

Todd M, Sclafani R, LANGAN T . Ovarian cancer cells that coexpress endogenous Rb and p16 are insensitive to overexpression of functional p16 protein. Oncogene. 2000; 19(2):258-64. DOI: 10.1038/sj.onc.1203289. View

13.

Horn S, Leonardelli S, Sucker A, Schadendorf D, Griewank K, Paschen A . Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance. J Natl Cancer Inst. 2018; 110(6):677-681. DOI: 10.1093/jnci/djx271. View

14.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

15.

Li S, Bu L, Cai L . Cuproptosis: lipoylated TCA cycle proteins-mediated novel cell death pathway. Signal Transduct Target Ther. 2022; 7(1):158. PMC: 9106713. DOI: 10.1038/s41392-022-01014-x. View

16.

Arredondo M, Nunez M . Iron and copper metabolism. Mol Aspects Med. 2005; 26(4-5):313-27. DOI: 10.1016/j.mam.2005.07.010. View

17.

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

18.

Ashburner M, Ball C, Blake J, Botstein D, Butler H, Cherry J . Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000; 25(1):25-9. PMC: 3037419. DOI: 10.1038/75556. View

19.

Kulkarni M, Hardwick J . Programmed Cell Death in Unicellular Versus Multicellular Organisms. Annu Rev Genet. 2023; 57:435-459. PMC: 11491101. DOI: 10.1146/annurev-genet-033123-095833. View

20.

Cheng X, Yang F, Li Y, Cao Y, Zhang M, Ji J . The crosstalk role of CDKN2A between tumor progression and cuproptosis resistance in colorectal cancer. Aging (Albany NY). 2024; 16(12):10512-10538. PMC: 11236303. DOI: 10.18632/aging.205945. View